These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

355 related articles for article (PubMed ID: 27898414)

  • 1. Outcomes after a 1-Year Treatment with Ranibizumab for Diabetic Macular Edema in a Clinical Setting.
    Hrarat L; Fajnkuchen F; Boubaya M; Lévy V; Sarda V; Grenet T; Nghiem-Buffet S; Chaine G; Giocanti-Auregan A
    Ophthalmologica; 2016; 236(4):207-214. PubMed ID: 27898414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A multicenter, 12-month randomized study comparing dexamethasone intravitreal implant with ranibizumab in patients with diabetic macular edema.
    Callanan DG; Loewenstein A; Patel SS; Massin P; Corcóstegui B; Li XY; Jiao J; Hashad Y; Whitcup SM
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):463-473. PubMed ID: 27632215
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Real-World Outcomes of Ranibizumab Treatment for Diabetic Macular Edema in a United Kingdom National Health Service Setting.
    Patrao NV; Antao S; Egan C; Omar A; Hamilton R; Hykin PG; Sivaprasad S; Rajendram R;
    Am J Ophthalmol; 2016 Dec; 172():51-57. PubMed ID: 27637784
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive factors of better outcomes by monotherapy of an antivascular endothelial growth factor drug, ranibizumab, for diabetic macular edema in clinical practice.
    Sato S; Shinoda H; Nagai N; Suzuki M; Uchida A; Kurihara T; Kamoshita M; Tomita Y; Iyama C; Minami S; Yuki K; Tsubota K; Ozawa Y
    Medicine (Baltimore); 2017 Apr; 96(16):e6459. PubMed ID: 28422835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Sustained Benefits from Ranibizumab for Central Retinal Vein Occlusion with Macular Edema: 24-Month Results of the CRYSTAL Study.
    Larsen M; Waldstein SM; Priglinger S; Hykin P; Barnes E; Gekkieva M; Das Gupta A; Wenzel A; Monés J;
    Ophthalmol Retina; 2018 Feb; 2(2):134-142. PubMed ID: 31047340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy of Ranibizumab in Eyes with Diabetic Macular Edema and Macular Nonperfusion in RIDE and RISE.
    Reddy RK; Pieramici DJ; Gune S; Ghanekar A; Lu N; Quezada-Ruiz C; Baumal CR
    Ophthalmology; 2018 Oct; 125(10):1568-1574. PubMed ID: 29752001
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diabetic macular oedema treated with intravitreal anti-vascular endothelial growth factor - 2-4 years follow-up of visual acuity and retinal thickness in 566 patients following Danish national guidelines.
    Hodzic-Hadzibegovic D; Sander BA; Monberg TJ; Larsen M; Lund-Andersen H
    Acta Ophthalmol; 2018 May; 96(3):267-278. PubMed ID: 29240306
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of two individualized treatment regimens with ranibizumab for diabetic macular edema.
    Ebneter A; Waldmeier D; Zysset-Burri DC; Wolf S; Zinkernagel MS
    Graefes Arch Clin Exp Ophthalmol; 2017 Mar; 255(3):549-555. PubMed ID: 27714513
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of Cataract Surgery during Treatment with Ranibizumab in Patients with Diabetic Macular Edema.
    Moshfeghi AA; Shapiro H; Lemmon LA; Gune S
    Ophthalmol Retina; 2018 Feb; 2(2):86-90. PubMed ID: 31047350
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A noninterventional study to monitor patients with diabetic macular oedema starting treatment with ranibizumab (POLARIS).
    Stefanickova J; Cunha-Vaz J; Ulbig M; Pearce I; Fernández-Vega Sanz A; Theodossiadis P; Kodjikian L; Izmailov A; Muston D; Vassilev Z; Lamotte B; Tückmantel C; Friedl S; Altemark A; Schwarz HJ; Katz T;
    Acta Ophthalmol; 2018 Dec; 96(8):e942-e949. PubMed ID: 29696809
    [TBL] [Abstract][Full Text] [Related]  

  • 11. One-Year Results of Using a Treat-and-Extend Regimen without a Loading Phase with Anti-VEGF Agents in Patients with Treatment-Naive Diabetic Macular Edema.
    Schwarzer P; Ebneter A; Munk M; Wolf S; Zinkernagel MS
    Ophthalmologica; 2019; 241(4):220-225. PubMed ID: 30654365
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Outcomes with As-Needed Ranibizumab after Initial Monthly Therapy: Long-Term Outcomes of the Phase III RIDE and RISE Trials.
    Boyer DS; Nguyen QD; Brown DM; Basu K; Ehrlich JS;
    Ophthalmology; 2015 Dec; 122(12):2504-13.e1. PubMed ID: 26452713
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Dexamethasone for unresponsive diabetic macular oedema: optical coherence tomography biomarkers.
    Bonfiglio V; Reibaldi M; Pizzo A; Russo A; Macchi I; Faro G; Avitabile T; Longo A
    Acta Ophthalmol; 2019 Jun; 97(4):e540-e544. PubMed ID: 30318792
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Real-life experience of ranibizumab for diabetic macular edema in Taiwan.
    Tsai MJ; Hsieh YT; Peng YJ
    Int Ophthalmol; 2019 Jul; 39(7):1511-1522. PubMed ID: 29926364
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Visual Outcomes Following Intravitreal Ranibizumab for Diabetic Macular Edema in a Pro Re Nata Protocol from Baseline: A Real-World Experience.
    James DGP; Mitkute D; Porter G; Vayalambrone D
    Asia Pac J Ophthalmol (Phila); 2019; 8(3):200-205. PubMed ID: 31165603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Evaluation of the New "SAVE" Protocol in Diabetic Macular Edema Over the Course of Anti-VEGF Treatment.
    Reznicek L; Bolz M; Garip A; Kampik A; Kernt M; Mayer WJ
    Curr Eye Res; 2016 Aug; 41(8):1082-1086. PubMed ID: 26580417
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy and safety of ranibizumab 0.5 mg in Chinese patients with visual impairment due to diabetic macular edema: results from the 12-month REFINE study.
    Li X; Dai H; Li X; Han M; Li J; Suhner A; Lin R; Wolf S;
    Graefes Arch Clin Exp Ophthalmol; 2019 Mar; 257(3):529-541. PubMed ID: 30645696
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Ranibizumab 0.5 mg for Diabetic Macular Edema with Bimonthly Monitoring after a Phase of Initial Treatment: 18-Month, Multicenter, Phase IIIB RELIGHT Study.
    Pearce I; Banerjee S; Burton BJ; Chakravarthy U; Downey L; Gale RP; Gibson J; Pagliarini S; Patel J; Sivaprasad S; Andrews C; Brittain C; Warburton J;
    Ophthalmology; 2015 Sep; 122(9):1811-9. PubMed ID: 26150052
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Switching therapy from bevacizumab to aflibercept for the management of persistent diabetic macular edema.
    Bahrami B; Hong T; Zhu M; Schlub TE; Chang A
    Graefes Arch Clin Exp Ophthalmol; 2017 Jun; 255(6):1133-1140. PubMed ID: 28238195
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Association between characteristics of foveal cystoid spaces and short-term responsiveness to ranibizumab for diabetic macular edema.
    Murakami T; Suzuma K; Uji A; Yoshitake S; Dodo Y; Fujimoto M; Yoshitake T; Miwa Y; Yoshimura N
    Jpn J Ophthalmol; 2018 May; 62(3):292-301. PubMed ID: 29460019
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.